#1 Clinical Trials Search in Europe

Dc-806

DC-806 is an investigational drug currently being studied in clinical trials for its potential in treating plaque psoriasis and other conditions. These trials aim to evaluate the drug’s safety, effectiveness, and how it interacts with the body. Researchers are conducting various studies to understand how DC-806 works, its effects on healthy individuals and patients with psoriasis, and how it may interact with other medications.

Table of Contents

What is DC-806?

DC-806 is a new drug being developed to treat moderate to severe plaque psoriasis. Plaque psoriasis is a chronic skin condition that causes red, scaly patches on the skin. This medication is currently undergoing clinical trials to evaluate its effectiveness and safety[1].

DC-806 is administered orally as tablets, making it potentially more convenient for patients compared to some other psoriasis treatments that require injections or topical applications[2].

How DC-806 Works

While the exact mechanism of action is not explicitly stated in the provided information, DC-806 likely works by targeting specific pathways involved in the inflammatory process of psoriasis. Many modern psoriasis treatments work by modulating the immune system to reduce inflammation and slow down the rapid skin cell growth characteristic of the condition.

Clinical Trials

DC-806 is currently being studied in several clinical trials:

  1. Phase 1 Mass Balance and Pharmacokinetics Study: This study aims to understand how DC-806 is processed and eliminated by the body. It involves healthy male participants and uses a special form of the drug labeled with a radioactive tracer ([14C]-DC-806) to track its movement through the body[1].

  2. Phase 1 Drug Interaction Studies: These studies are investigating how DC-806 interacts with other medications. They look at the effects of drugs that influence liver enzymes (specifically CYP3A4) on DC-806 levels in the body, as well as how DC-806 might affect the levels of other commonly used medications[3][4].

  3. Phase 2 Efficacy and Safety Study: This is a 12-week study evaluating how well DC-806 works for treating moderate to severe plaque psoriasis. It compares different doses of DC-806 to a placebo (a pill with no active ingredient) to determine its effectiveness and safety[2].

Potential Benefits

The main goal of DC-806 treatment is to significantly reduce the severity of plaque psoriasis symptoms. The primary measure of success in the clinical trial is achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI-75) score. This means that the treatment aims to clear up a large portion of the psoriasis plaques and reduce their severity[2].

If proven effective, DC-806 could offer several advantages:

  • Oral administration, which may be more convenient than injections or topical treatments
  • Potential for at-home use without the need for frequent clinic visits
  • A new option for patients who haven’t responded well to other treatments

Safety and Side Effects

As DC-806 is still in clinical trials, its full safety profile is not yet established. The ongoing studies are carefully monitoring for any side effects or safety concerns. Some key safety measures being evaluated include:

  • Treatment-emergent adverse events (TEAEs): These are any new medical problems or worsening of existing problems that occur during treatment.
  • Serious adverse events (SAEs): These are more severe side effects that may require hospitalization or are life-threatening.
  • TEAEs leading to discontinuation: This refers to side effects severe enough that participants need to stop taking the medication[2].

It’s important to note that all medications can have side effects, and the purpose of these trials is to determine if the benefits of DC-806 outweigh any potential risks.

Drug Interactions

Researchers are conducting studies to understand how DC-806 might interact with other medications. This is crucial information for ensuring the safe use of the drug. Some key points about potential drug interactions include:

  • Effect of other drugs on DC-806: Studies are looking at how drugs like itraconazole (an antifungal medication) and carbamazepine (used for epilepsy and nerve pain) affect the levels of DC-806 in the body. These drugs can influence liver enzymes that process medications[3].

  • Effect of DC-806 on other drugs: Researchers are also investigating whether DC-806 affects the levels of other commonly used medications in the body. This includes drugs like midazolam (a sedative), repaglinide (for diabetes), digoxin (for heart conditions), and rosuvastatin (for high cholesterol)[4].

Understanding these interactions will help doctors make informed decisions about prescribing DC-806 alongside other medications, if it becomes approved for use.

Aspect Details
Drug Name DC-806 (also known as S011806 or LY4100504)
Administration Oral (tablets or capsules)
Primary Condition Studied Moderate to severe plaque psoriasis
Study Types Phase 1 and Phase 2 clinical trials
Key Objectives Safety, efficacy, tolerability, pharmacokinetics, drug interactions
Main Outcome Measures PASI-75, adverse events, drug concentration in blood and plasma
Special Studies Mass balance, drug-drug interactions, effects on CYP450 enzymes
Study Populations Healthy volunteers and patients with plaque psoriasis

FAQ

  • What is DC-806? DC-806 is an experimental drug being studied for the treatment of plaque psoriasis. It is taken orally in tablet or capsule form and is currently undergoing clinical trials to assess its safety and effectiveness.
  • What conditions is DC-806 being studied for? The main condition being studied for DC-806 treatment is moderate to severe plaque psoriasis. However, some trials are also conducted on healthy volunteers to understand the drug's behavior in the body.
  • How is DC-806 administered? DC-806 is administered orally, typically in the form of tablets or capsules. The dosing regimen may vary depending on the specific trial and study phase.
  • What are the main objectives of the DC-806 clinical trials? The main objectives include assessing the drug's safety, tolerability, pharmacokinetics (how the body processes the drug), and efficacy in treating plaque psoriasis. Some trials also aim to understand how DC-806 interacts with other medications.
  • Are there any known side effects of DC-806? As DC-806 is still in clinical trials, the full range of potential side effects is not yet known. The trials are designed to monitor and report any adverse events that participants may experience during the study period.

Ongoing Clinical Trials on Dc-806

  • A study to examine how the body processes and removes DC-806 in healthy male volunteers

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Hungary Poland Spain

Glossary

  • Plaque Psoriasis: A common form of psoriasis characterized by raised, red patches covered with a silvery white buildup of dead skin cells or scales, typically on the knees, elbows, scalp, and lower back.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Efficacy: The ability of a drug to produce the desired therapeutic effect.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Psoriasis Area of Severity Index (PASI): A tool used to measure the severity and extent of psoriasis, often used in clinical trials to assess treatment effectiveness.
  • Cytochrome P450 (CYP): A family of enzymes involved in drug metabolism in the body, particularly important for understanding drug interactions.
  • Drug-Drug Interaction: A situation in which one drug affects the activity of another drug when both are administered together.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the effects of the investigational drug.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Half-life: The time it takes for the amount of a drug in the body to be reduced by half.

References

  1. https://clinicaltrials.gov/study/NCT06045000
  2. https://clinicaltrials.gov/study/NCT05896527
  3. https://clinicaltrials.gov/study/NCT05994807
  4. https://clinicaltrials.gov/study/NCT06092931